Precision Across Blood and Tissue
Quanterix advances precision across research and healthcare by transforming biomarker data into meaningful insight; driving discovery, guiding clinical decisions, and accelerating breakthroughs from bench to bedside.
instruments deployed globally
peer-reviewed publications
Partnerships with top 20 pharma, CROs, and diagnostics labs
One Company. Two Modalities. Full-Spectrum Biomarker Clarity
Quanterix delivers matched biomarker insights across blood, CSF and tissue. While liquid assays detect systemic signals, spatial tissue analysis maps those signals to their biological origin.
- Power research in neurology, oncology, inflammation and beyond
- Follow the same biomarker across matrices
- Ready for validated use: CLIA-ready Simoa assays & standardized spatial panels
Dual Modality. Total Insight.
Explore our solutions and services.
Simoa Instruments
From Benchtop to fully automated, our analyzers deliver high throughput biomarker quantification with true pg/mL resolution across matrices.
Simoa Assay Kits and Reagents
Measure low abundance biomarkers with unmatched sensitivity, precision and reproducibility- across neurology, immunology, oncology, and more.
Spatial Biology Instruments
Capture high-plex spatial proteomic data at single cell resolution with imaging platforms designed for translational research and clinical workflows.
Spatial Biology Assays & Reagents
Unlock tissue-based biomarker signatures with high-plex spatial proteomics panels built for discovery, validation, and CDx development.
Simoa® Accelerator Laboratory
Empowering researchers to bring new discoveries in disease and treatment to the forefront with our Simoa precision instruments, wide-ranging menu of assay kits, and custom assay development services.
Lucent Diagnostics
Learn how we’re bringing the power of p-Tau to the clinic with the LucentAD blood test- advancing Alzheimer’s care through precision diagnostics powered by Simoa.
Built for Clinical Rigor. Proven in Practice.
Every Matrix. Every Disease. Every Decision.
Your decisions deserve more than just data; they deserve validated, reproducible insights. Quanterix platforms are built for reliability, precision, and trust.
- Consistent detection, not missed samples
- True pg/mL reporting, no arbitrary units
- <10% CVs across matrices
- Validated for clinical trials and CLIA labs
Data You Can Trust, Decisions You Can Act On
Track neurodegeneration and injury biomarkers to support early detection, disease monitoring, and therapeutic evaluation.
Power oncology research with dual modality data, track systemic immune activation through blood and map the tumor microenvironment in tissue with spatial proteomics.
Profile immune activation and suppression across matrices- quantifying cytokines in blood and characterize immune cell architecture in tissue to reveal disease drivers and treatment effects.
Asses cardiology risk and injury with systemic biomarkers and extend insights with spatial analysis of tissue inflammation and remodeling.
Capture host-pathogen interactions with high sensitivity, viral and cytokine detection in blood, paired with tissue level immune profiling for localized response insights.
Proven. Scalable. Ready Now.
Whether you’re designing a clinical trial, validating a diagnostic, or developing next-gen therapies, Quanterix is your partner in precision biomarker innovation. Together with Akoya, we unify liquid and spatial analysis to give you the clearest picture of disease biology.
Cancer
Mapping the Tumor Immune Microenvironment: Spatial Biology Insights into Immunotherapy Response in NSCLC
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
Synaptic Dysfunction and Neuroinflammation: Complementary Pathways Driving Cognitive Decline
Accelerator Laboratory Services: The Biomarker Powerhouse
Proteomics in Transition: From Discovery to Diagnostic Utility
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
YKL-40 Emerges as a Key Indicator of Neuroinflammatory-Driven Tau Pathology and Brain Atrophy in Alzheimer’s Disease
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
Looking Ahead: Key Takeaways from AAIC 2025
The 2025 Alzheimer’s Association International Conference (AAIC) brought the global neuroscience community to share breakthrough science, policy priorities, and tools like never before. It was an incredible week of conversation, innovation and…
Neurology
AAIC 2025: A Showcase of Simoa-Powered Innovation and Integration in Alzheimer’s Research
Next week, researchers from around the globe will gather in Toronto for the Alzheimer’s Association International Conference (AAIC) 2025, and Quanterix is proud to be at the center of the…
Quanterix Releases Financial Results for the Second Quarter of 2026
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Quanterix Names Jim Gute Chief Commercial Officer
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
BILLERICA, Mass.—June 9, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company’s new Chief…
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business BILLERICA, Mass.–June 4, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the…
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…
Tertiary Lymphoid Structures in Cancer Immunotherapy: Insights and Perspectives
Tertiary lymphoid structures (TLS) have emerged as critical components of the tumor microenvironment, influencing immune responses and clinical outcomes in cancer.
Discover How to Achieve High Sensitivity Cytokine Biomarker Quantification in Complex Samples Using Simoa Assays
Introducing the Metabolism Spike-in Module for IO60
Neurology
NfL Fact Sheet
Neurofilament light (NfL) has emerged in recent years as a blood-based biomarker with the potential to aid in the improvement of early diagnosis and patient care of neuro-axonal injury and…
Neurology
Cytokine 4-Plex Advantage PLUS Product Flyer
Ultra-Sensitive, Fully Automated Simoa® Cytokine 4-Plex Advantage PLUS Assays Three panels, 11 essential cytokine biomarkers, femtogram sensitivity With Simoa® ultra-sensitive protein quantification, the cutting-edge Advantage PLUS assay platform, and full…
PhenoCode Discovery Immune Activation and Proliferation Human Protein Module
Neurology
Brain-Derived Tau (BD-Tau) Fact Sheet
Brain-derived Tau (BD-Tau) is one of the latest additions to the growing neurology biomarker family that holds promise to improve the accuracy in the identification and staging of neurodegeneration in…
Neurology
Simoa® Technology Powering Advancements in Neurology
Flyer Quanterix empowers researchers with cutting-edge Simoa® digital immunoassays that measure both established and emerging biomarkers in neurology. Simoa® technology sets the gold standard for early biomarker detection in serum,…
Immunology
Measure Ultra Low Levels of IFN-α with Simoa® Advantage PLUS
Flyer Unlock new possibilities with Simoa® IFN-α Multi-Subtype (MS) Advantage PLUS, enabling the measurement of circulating IFN-α at femtogram levels. Whether you‘re advancing research on the immune response or evaluating…
Homebrew
Quanterix Accelerator Laboratory Brochure
The Quanterix Accelerator Laboratory is a dedicated laboratory environment for digitized biomarker research, custom assay development, and clinical sample testing using our Simoa® and Akoya technologies. The Quanterix Accelerator Lab offers…
Resources
Explore our library of resources, posts and materials.
Support
Contact our team for customer support, distributor inquiries, or general questions.